Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 381 of 5804
-
Chemo-Free start shows promise for High-Risk lymphoma in older adults
Disease control OngoingThis study is a phase II clinical trial and is divided into three stages. Stage 1: Chemotherapy-free phase. All subjects will receive "Serplulimab, Chidamide, and Rituximab (SCR) therapy". After 2 treatment cycles, efficacy will be evaluated. Subjects who achieve CR or CMR will …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New hope for Hard-to-Treat breast cancer: Dato-DXd trial opens
Disease control Recruiting nowA study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New COVID shot tested in vulnerable kids
⭐️ VACCINE ⭐️ OngoingThe purpose of this study is to learn about the safety, tolerability, and immunogenicity of an updated vaccine against COVID-19, called BNT162b2 (2025/2026 formulation). This study is seeking participants 5 through 11 years of age who: * have at least 1 underlying condition tha…
Phase: PHASE3 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:05 UTC
-
New drug shows promise for Long-Term bipolar depression control
Disease control ENROLLING_BY_INVITATIONX-CEED-OLE is a Phase 3, multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner in adult participants who successfully completed an antecendent Phase 3 azetukalner bipolar depression study.
Phase: PHASE3 • Sponsor: Xenon Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Laser eye surgery could prevent blindness in rare genetic condition
Prevention Recruiting nowThe goal of this clinical trial is to prospectively document to what extent the OSC/SS prophylactic laser retinopexy procedure works to prevent retinal detachment in SS in children and adults. Researchers will compare the OSC/SS procedure in SS to the natural progression of SS t…
Phase: NA • Sponsor: Helen Keller Eye Research Foundation • Aim: Prevention
Last updated Jul 03, 2026 00:00 UTC
-
New drug cocktail aims to make inoperable kidney tumors removable
Disease control Recruiting nowAll subjects will receive zanzalintinib 100mg orally (PO) once daily plus nivolumab standard of care dosing (i.e., 240mg IV every 2 weeks or 480mg IV every 4 weeks) for a total of 12 weeks, followed by restaging scan/evaluation for surgical operability and an adaptive approach th…
Phase: PHASE2 • Sponsor: Qian Qin • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for kidney cancer: experimental combo targets resistant tumors
Disease control Not yet recruitingThis study is A prospective,single arm, multicenter clinical study of BTLA monoclonal antibody JS004 (B/T lymphocyte attenuator factor monoclonal antibody) in combination with toripalimab in patients with unresectable or advanced renal cell carcinoma who had failed previous immun…
Phase: PHASE2 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New antibody cocktail shows promise in lung cancer trial
Disease control Recruiting nowLung cancer is the leading cause of cancer-related deaths worldwide. According to the 2023 global cancer statistics, there are approximately 2.47 million new cases and 1.76 million deaths of lung cancer annually, accounting for 18.4% of all cancer deaths. Among them, driver gene …
Phase: PHASE2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Zapping resistant tumors: could radiation keep breast cancer therapy working longer?
Disease control Recruiting nowThe Oligopro-Breast trial is a Phase II study targeting women with ER+/HER2- metastatic breast cancer who have been on endocrine therapy and/or CDK4/6 inhibitors for at least 6 months, and show progressive disease at 1-3 extracranial metastases, which are treatable locally. The t…
Phase: NA • Sponsor: Jules Bordet Institute • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Promising drug targets HER2 cancers in new trial
Disease control Recruiting nowAlterations in the HER2 gene are involved in the development of cancer. These abnormalities are found at highly variable rates (from approximately 2% to 60%) in cancers of the lung, breast, stomach, bile ducts, salivary glands, colon, endometrium, uterus, bladder, bones, blood, e…
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New immunotherapy cocktail aims to tackle tough lung cancer
Disease control Recruiting nowThe goal of this clinical trial is to learn if different combinations of a drug called Ivonescimab, along with chemotherapy and other investigational drugs, are safe and effective for the initial treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). The main…
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Morning vs. evening: can timing boost melanoma treatment?
Disease control Recruiting nowThis phase II trial tests the safety and effectiveness of giving ipilimumab and nivolumab in the morning compared to other times of day in treating patients with melanoma that is stage IV or that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodie…
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Gene therapy trial aims to help people with angelman syndrome communicate better
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of MVX-220 gene therapy in children and adults with Angelman syndrome with UBE3A gene deletion, uniparental disomy, or imprinting center defect genotypes.
Phase: PHASE1, PHASE2 • Sponsor: MavriX Bio, LLC • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Mass STI treatment or pill after sex? major trial tests best bet for kenyan men
Disease control Recruiting nowMen who have sex with men (MSM) are at high risk for gonorrhea and chlamydia in Kenya, where nucleic acid amplification testing is not feasible and most infections therefore go undiagnosed. We propose an open-label randomized clinical trial with 2900 participants assigned to WHO-…
Phase: PHASE4 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New RSV vaccine trial targets younger High-Risk adults in china
⭐️ VACCINE ⭐️ Recruiting nowThe study will evaluate the immune response of the RSVPreF3 OA investigational vaccine in Chinese adults 18 to 59 years of age (YOA) who are at increased risk of respiratory syncytial virus (RSV) disease, in comparison with the immune response generated in older adults 60 YOA and…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:38 UTC
-
Immunotherapy after surgery may keep early lung cancer at bay
Disease control Recruiting nowA Randomized, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New eye injection aims to halt blindness from dry AMD in major trial
Disease control Recruiting nowThe purpose of this study is to collect efficacy and safety information of intravitreal injection for 3 experimental arms, including 2 dose levels of ONL1204 and 2 treatment frequencies in patients with GA associated with AMD. GA associated with AMD is one of the world's leading…
Phase: PHASE2 • Sponsor: ONL Therapeutics • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Personalized cancer test could match patients to best drugs
Diagnosis Recruiting nowDSEE-CRC is a top-tier Norwegian and Swedish public-private partnership for the development of µCAN, a unique patient-centric, therapy-guiding in vitro diagnostic test to improve cancer treatment outcomes for metastatic colorectal cancer patients. µCAN takes a cancer biopsy sampl…
Phase: NA • Sponsor: Oncosyne AS • Aim: Diagnosis
Last updated Jun 27, 2026 12:26 UTC
-
Glaucoma patients may soon ditch eye drops after cataract surgery
Disease control Recruiting nowThis trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
Phase: PHASE3 • Sponsor: SpyGlass Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug combo shows promise in shrinking cervical tumors before surgery
Disease control Recruiting nowCervical cancer ranks as the second most common malignancy of the female genital tract. According to the World Health Organization, there are 530,000 new cases and approximately 250,000 cervical-cancer-related deaths worldwide each year, with 80% of these deaths occurring in wome…
Phase: PHASE2 • Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC